Alexander P. Ivanov
Research Subjects
Research Interests
Alexander P. Ivanov has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Olga E. Ivanova
Federal State Autonomous Scientific Institution “Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences” (Institute of Poliomyelitis) (FSASI “Chumakov FSC R&D IBP RAS”), 108819 Moscow, Russia
6 shared publications E A Tkachenko
2 shared publicationsG V Rezapkin
2 shared publicationsV G Kozlov
2 shared publicationsA V Kiktenko
1 shared publicationA. A. Ishmuhametov
ФГУП «Предприятие по производству бактерийных и вирусных препаратов Института полиомиелита и вирусных энцефалитов им. М.П. Чумакова
1 shared publication
Latest Publications
- Open Access
- 20 August 2016
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 15 (4) , 59-64
Experimental Approaches to the Development of Inactivated Poliovirus Vaccine Based on Sabin Strains
The results of development of experimental series of inactivated poliovirus vaccine based on Sabin strains (s-IPV) using conventional modern techniques are presented. Comparative analysis of immunogenicity of the experimental s-IPV and commercial IPV prepared from «wild» poliovirus strains (Imovax, Sanofi Pasteur S.A., France) using several models of laboratory animals showed their identity regarding Sabin and «wild» strains. Original method (an ELISA using specific chicken egg yolk antibodies of class Y-IgY) for quantitative determination of D-antigen in elaboration of vaccine formulation has been developed and protected by patent; conventional control methods in accordance with the WHO and European Pharmacopoeia requirements have been adopted. Finally, at experimental level it was shown that basic characteristics of the s-IPV are comparable with those of commercial IPV prepared from «wild» poliovirus strains
- 20 August 2016
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 15 (4) , 59-64
Open AccessExperimental Approaches to the Development of Inactivated Poliovirus Vaccine Based on Sabin Strains
The results of development of experimental series of inactivated poliovirus vaccine based on Sabin strains (s-IPV) using conventional modern techniques are presented. Comparative analysis of immunogenicity of the experimental s-IPV and commercial IPV prepared from «wild» poliovirus strains (Imovax, Sanofi Pasteur S.A., France) using several models of laboratory animals showed their identity regarding Sabin and «wild» strains. Original method (an ELISA using specific chicken egg yolk antibodies of class Y-IgY) for quantitative determination of D-antigen in elaboration of vaccine formulation has been developed and protected by patent; conventional control methods in accordance with the WHO and European Pharmacopoeia requirements have been adopted. Finally, at experimental level it was shown that basic characteristics of the s-IPV are comparable with those of commercial IPV prepared from «wild» poliovirus strains
- 1 January 2015
- Vol. 60 (1) , 31-4
[Production of the polyclonal enterovirus antibodies of chicken (IgY) and its evaluation as alternative to the rabbit enterovirus neutralizing sera].
Experimental data show the usefulness of the Leghorn chicken as a producer of the enterovirus neutralizing antibodies (IgY). The resulting serum is not inferior to the specific activity of the commercial rabbit enterovirus diagnostic sera (EDS) in the neutralization reaction. The IgY have lower backgrounds than mammalian IgG and do not cause toxic effect to cell culture. Compared with the conventional manufacturing method EDS IgY, preparation process is much more effective: the number of serum producers is significantly lower, whereas the yield of the product is higher. Reduction of the volume of the immunogens, immunization cycle, and number of injections is also an advantage of this manufacturing method.
- 1 January 2015
- Vol. 60 (1) , 31-4
[Production of the polyclonal enterovirus antibodies of chicken (IgY) and its evaluation as alternative to the rabbit enterovirus neutralizing sera].
Experimental data show the usefulness of the Leghorn chicken as a producer of the enterovirus neutralizing antibodies (IgY). The resulting serum is not inferior to the specific activity of the commercial rabbit enterovirus diagnostic sera (EDS) in the neutralization reaction. The IgY have lower backgrounds than mammalian IgG and do not cause toxic effect to cell culture. Compared with the conventional manufacturing method EDS IgY, preparation process is much more effective: the number of serum producers is significantly lower, whereas the yield of the product is higher. Reduction of the volume of the immunogens, immunization cycle, and number of injections is also an advantage of this manufacturing method.
- 1 January 2014
- Vol. 59 (6) , 39-42
[An ELISA system based on the specific class Y (IgY) antibodies from egg yolks for the quantitative determination of D-antigen in inactivated poliovirus vaccines].
The results of the construction of the first Russian ELISA system for the quantitative determination of D-antigen of 1-3 poliovirus types in the preparations of inactivated poliovirus vaccines are presented. For the first time, this kind of system is based on the use of specific antibodies of class Y (IgY) from egg yolks of immunized hens. It was shown that this ELISA system is specific, sufficiently sensitive, and can be used for quantitative determination of D-antigen of 1-3 poliovirus types in inactivated poliovirus vaccines.
- 1 January 2014
- Vol. 59 (6) , 39-42
[An ELISA system based on the specific class Y (IgY) antibodies from egg yolks for the quantitative determination of D-antigen in inactivated poliovirus vaccines].
The results of the construction of the first Russian ELISA system for the quantitative determination of D-antigen of 1-3 poliovirus types in the preparations of inactivated poliovirus vaccines are presented. For the first time, this kind of system is based on the use of specific antibodies of class Y (IgY) from egg yolks of immunized hens. It was shown that this ELISA system is specific, sufficiently sensitive, and can be used for quantitative determination of D-antigen of 1-3 poliovirus types in inactivated poliovirus vaccines.
- 15 February 2006
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 193 (4) , 598-600
1,25‐Dihydroxyvitamin D3 Enhances Systemic and Mucosal Immune Responses to Inactivated Poliovirus Vaccine in Mice
1,25-Dihydroxyvitamin D3 (DHVD3) coadministered with monovalent inactivated poliovirus vaccine (IPV) of all 3 serotypes significantly enhances antipoliovirus systemic and mucosal immunity in mice. Although serum immunoglobulin G antibodies are significantly higher in serotypes 2 and 3, and although salivary immunoglobulin A is significantly increased in serotypes 1 and 3, DHVD3 had the most dramatic effect on the level of neutralizing serum antibodies of all 3 IPV serotypes. These findings suggest a possible use of vitamin D3 as an adjuvant for currently used and proposed new Sabin IPV s.
- 15 February 2006
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 193 (4) , 598-600
1,25‐Dihydroxyvitamin D3 Enhances Systemic and Mucosal Immune Responses to Inactivated Poliovirus Vaccine in Mice
1,25-Dihydroxyvitamin D3 (DHVD3) coadministered with monovalent inactivated poliovirus vaccine (IPV) of all 3 serotypes significantly enhances antipoliovirus systemic and mucosal immunity in mice. Although serum immunoglobulin G antibodies are significantly higher in serotypes 2 and 3, and although salivary immunoglobulin A is significantly increased in serotypes 1 and 3, DHVD3 had the most dramatic effect on the level of neutralizing serum antibodies of all 3 IPV serotypes. These findings suggest a possible use of vitamin D3 as an adjuvant for currently used and proposed new Sabin IPV s.
- 30 June 2005
- Published by Elsevier in Journal of Virological Methods
- Vol. 126 (1-2) , 45-52
Determination of poliovirus-specific IgA in saliva by ELISA tests
- 30 June 2005
- Published by Elsevier in Journal of Virological Methods
- Vol. 126 (1-2) , 45-52
Determination of poliovirus-specific IgA in saliva by ELISA tests
- 1 May 2005
- Published by Taylor & Francis in Human Vaccines
- Vol. 1 (3) , 102-105
Poliovirus-Binding Inhibition ELISA for Evaluation of Immune Response to Oral Poliovirus Vaccine: A Possible Alternative to the Neutralization Test
This study describes an ELISA variant (Binding Inhibition ELISA, BI ELISA) for the quantitative determination of neutralization-relevant antibodies to polioviruses. The test differs from previously described analogs by utilizing polyclonal immune reagents: capture antibodies and biotin-labeled detecting antibodies. The BI ELISA was compared with the conventional neutralization test (NT) by testing live Sabin and wild-type poliovirus strains. The comparison of 68 serum samples taken from Oral Poliovirus Vaccine (OPV) recipients showed 100 % specificity and sensitivity for Sabin 1 and Sabin 2, and 100 % sensitivity and 97 % specificity for Sabin 3. Good correlations (r = 0.7, 0.77, 0.65 for Sabin 1, 2, 3, respectively) were demonstrated between the NT and BI ELISA results. These results indicate that the BI ELISA can be used as a reliable alternative to the NT for determination of neutralization-relevant antibodies to polioviruses in vaccinees and in large-scale sero-epidemiological studies.
- 1 May 2005
- Published by Taylor & Francis in Human Vaccines
- Vol. 1 (3) , 102-105
Poliovirus-Binding Inhibition ELISA for Evaluation of Immune Response to Oral Poliovirus Vaccine: A Possible Alternative to the Neutralization Test
This study describes an ELISA variant (Binding Inhibition ELISA, BI ELISA) for the quantitative determination of neutralization-relevant antibodies to polioviruses. The test differs from previously described analogs by utilizing polyclonal immune reagents: capture antibodies and biotin-labeled detecting antibodies. The BI ELISA was compared with the conventional neutralization test (NT) by testing live Sabin and wild-type poliovirus strains. The comparison of 68 serum samples taken from Oral Poliovirus Vaccine (OPV) recipients showed 100 % specificity and sensitivity for Sabin 1 and Sabin 2, and 100 % sensitivity and 97 % specificity for Sabin 3. Good correlations (r = 0.7, 0.77, 0.65 for Sabin 1, 2, 3, respectively) were demonstrated between the NT and BI ELISA results. These results indicate that the BI ELISA can be used as a reliable alternative to the NT for determination of neutralization-relevant antibodies to polioviruses in vaccinees and in large-scale sero-epidemiological studies.
- 1 April 2005
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 4 (2) , 167-172
ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines
This review describes several enzyme-linked immunosorbent assay (ELISA) techniques proposed to replace the neutralization test for detecting neutralization-relevant antibodies to polioviruses in recipients of inactivated poliovirus vaccine and oral poliovirus vaccine, and for seroepidemiologic studies. Comparisons of results from ELISA and the neutralization test suggest that ELISA variants, based on the principle of blocking or binding inhibition that emulate the neutralization test, might offer an alternative to the neutralization test. However, to replace the neutralization test with ELISA would first require extensive studies with very large numbers of serum samples, including sera having low titers of neutralizing antibodies, in order to obtain reliable and statistically sound validation.
- 1 April 2005
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 4 (2) , 167-172
ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines
This review describes several enzyme-linked immunosorbent assay (ELISA) techniques proposed to replace the neutralization test for detecting neutralization-relevant antibodies to polioviruses in recipients of inactivated poliovirus vaccine and oral poliovirus vaccine, and for seroepidemiologic studies. Comparisons of results from ELISA and the neutralization test suggest that ELISA variants, based on the principle of blocking or binding inhibition that emulate the neutralization test, might offer an alternative to the neutralization test. However, to replace the neutralization test with ELISA would first require extensive studies with very large numbers of serum samples, including sera having low titers of neutralizing antibodies, in order to obtain reliable and statistically sound validation.
- 1 March 1992
- Vol. 72 (1) , 73-4
Serological investigations of Chikungunya virus in the Republic of Guinea.
- 1 March 1992
- Vol. 72 (1) , 73-4
Serological investigations of Chikungunya virus in the Republic of Guinea.
- 1 January 1986
- Vol. 30 (1) , 79-85
Hemorrhagic fever with renal syndrome in Czechoslovakia: detection of antigen in small terrestrial mammals and specific serum antibodies in man.
A direct ELISA technique was used for demonstration of HFRS virus antigen in suspensions of the lungs obtained from 774 wild small mammals belonging to 13 zoological species trapped in 21 localities in Czechoslovakia between 1983 and 1984. Western serotype of HFRS virus was demonstrated in the lungs of 8 Microtus arvalis voles caught in the areas of central Bohemia, southern Moravia and western Slovakia, and in one Clethrionomys glareolus vole from the area of eastern Slovakia. The eastern serotype antigen was found in one Apodemus agrarius field mouse captured in the area of eastern Slovakia. The antigen titres as determined in the lungs of these rodents by the ELISA and RIA techniques were relatively high. Human sera examined for the presence of HFRS-specific antibody by the indirect fluorescence and RIA techniques were 76 serum specimens from chronic kidney patients treated by hemodialysis and 349 sera of adult males over 35 years of age coming from various districts of Bohemia and Moravia. Antibodies against HFRS virus antigen were found in 4 sera obtained from northern Bohemian men. The results provide the evidence which suggests that the natural foci of HFRS are likely to occur across much of the Czechoslovak territory, and confirms the focality of this infection in at least some of the localities characteristic in the 1950s and 1960s of the incidence of severe sporadic cases of HFRS.
- 1 January 1986
- Vol. 30 (1) , 79-85
Hemorrhagic fever with renal syndrome in Czechoslovakia: detection of antigen in small terrestrial mammals and specific serum antibodies in man.
A direct ELISA technique was used for demonstration of HFRS virus antigen in suspensions of the lungs obtained from 774 wild small mammals belonging to 13 zoological species trapped in 21 localities in Czechoslovakia between 1983 and 1984. Western serotype of HFRS virus was demonstrated in the lungs of 8 Microtus arvalis voles caught in the areas of central Bohemia, southern Moravia and western Slovakia, and in one Clethrionomys glareolus vole from the area of eastern Slovakia. The eastern serotype antigen was found in one Apodemus agrarius field mouse captured in the area of eastern Slovakia. The antigen titres as determined in the lungs of these rodents by the ELISA and RIA techniques were relatively high. Human sera examined for the presence of HFRS-specific antibody by the indirect fluorescence and RIA techniques were 76 serum specimens from chronic kidney patients treated by hemodialysis and 349 sera of adult males over 35 years of age coming from various districts of Bohemia and Moravia. Antibodies against HFRS virus antigen were found in 4 sera obtained from northern Bohemian men. The results provide the evidence which suggests that the natural foci of HFRS are likely to occur across much of the Czechoslovak territory, and confirms the focality of this infection in at least some of the localities characteristic in the 1950s and 1960s of the incidence of severe sporadic cases of HFRS.
- 1 March 1984
- Vol. 29 (2) , 191-5
[Results of a serological examination of amyotrophic lateral sclerosis patients].
Examinations of specimens from 12 patients with amyotrophic lateral sclerosis (ALS) by means of enzyme-labeled immunosorbent assay (ELISA) and solid-phase radioimmunoassay ( SPIRA ) demonstrated antibody to lymphocytic choriomeningitis virus (LCM) in the blood sera of 3 patients and antigens of LCM virus in sera of 2 other patients. LCM virus antigen was also found in organs of a patient who died of ALS. LCM virus was isolated from the serum of one patient positive for LCM antigen by inoculation of newborn white mice. The new isolate (the Kanta -220 strain) examined by electron microscope was shown to have some morphological differences from the museum strain CA-1371 of LCM virus available in the laboratory.
- 1 March 1984
- Vol. 29 (2) , 191-5
[Results of a serological examination of amyotrophic lateral sclerosis patients].
Examinations of specimens from 12 patients with amyotrophic lateral sclerosis (ALS) by means of enzyme-labeled immunosorbent assay (ELISA) and solid-phase radioimmunoassay ( SPIRA ) demonstrated antibody to lymphocytic choriomeningitis virus (LCM) in the blood sera of 3 patients and antigens of LCM virus in sera of 2 other patients. LCM virus antigen was also found in organs of a patient who died of ALS. LCM virus was isolated from the serum of one patient positive for LCM antigen by inoculation of newborn white mice. The new isolate (the Kanta -220 strain) examined by electron microscope was shown to have some morphological differences from the museum strain CA-1371 of LCM virus available in the laboratory.